Success Metrics

Clinical Success Rate

100.0%

Based on 4 completed trials

Completion Rate

100%(4/4)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_1

33%

Ph phase_2

33%

Ph phase_3

17%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

2(40.0%)

Phase 2Efficacy & side effects

2(40.0%)

Phase 3Large-scale testing

1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Other(2)

Detailed Status

Completed4

unknown2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 12 (40.0%)

Phase 22 (40.0%)

Phase 31 (20.0%)

Trials by Status

unknown233%

completed467%

Recent Activity

0 active trials

Showing 5 of 6

unknownphase_3

A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer

NCT00539383

View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials

NCT03613181Phase 3

ANG1005 in Leptomeningeal Disease From Breast Cancer

Unknown

NCT02048059Phase 2

ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases

Completed

NCT01967810Phase 2

ANG1005 in Patients With Recurrent High-Grade Glioma

Completed

NCT02755987

Expanded Access to ANG1005 for Individual Patients

Unknown

NCT00539383Phase 1

A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer

Completed

NCT00539344Phase 1

A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma

Completed

All 6 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 6